The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Open accessAbstract
Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Still, often phenotypes such as drug response observed in vitro have been unable to mirror in vivo models, likely due to factors missing in the tumor microenvironment that are absent from homogeneous cell lines cultures such as stromal and immune cells (Beaufort et al., 2014).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Beaufort et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 1×
“Sequence analysis and variant verification was performed as described previously [26,27].”
MethodThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“analysed genomic data for 47 ovarian cancer cell lines from the CCLE collection [13] for genetic similarity to highgrade serous ovarian carcinomas from the TCGA data [4,57].”
BackgroundIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
The Massachusetts Institute of Technology
Endowed, S. C. F. (1999) · Anthropology News · doi:10.1111/an.1999.40.2.6 · Cited by 3,132
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundOne Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23
Fogh, J., Fogh, J. M., & Orfeo, T. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/59.1.221 · Cited by 1,599
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484 · cited 1×
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
BackgroundNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458 · cited 7×
“We used the expression data for 267 malignant ovarian carcinomas (GSE9891) [11] to determine the clinical significance of the morphological subtypes seen in our cell lines.”
BackgroundMethodInfluential
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–406 of 406
Perello-Trias, M. T., Serrano‐Muñoz, A. J., Segura‐Sampedro, J. J., Duarte, A. Q., Ramis, J. M., & Monjo, M. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70280
“18,20,24,25 We then implemented a preperitoneal implantation strategy in which OVCAR-3Luc cells were directly inoculated onto the peritoneal membrane to mimic residual tumor nodules remaining after CRS.”
Deng, O., Nepomuceno, T. C., Fang, B., Welsh, E. A., Izumi, V., Martin, R. H., George, E. M., Koomen, J. M., Monteiro, A. N., & Rix, U. (2026) · PLoS ONE · doi:10.1371/journal.pone.0357365
陈立天, Fu, P., Wu, S., Chen, B., & Wen, X. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1943981
Forgie, B. N., Prakash, R., Marno, D., Abdalbari, F. H., Zorychta, E., Noman, A. S. M., Goyeneche, A. A., Gilbert, L., Burnier, J. V., & Telleria, C. M. (2026) · Pharmaceuticals · doi:10.3390/ph19101665 · Cited by 2
Metadata
- Authors
- Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., Koudijs, M. J., Brenton, J. D., Berns, E. M. J. J., & Helleman, J.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- University of Cambridge (GB)
- University Medical Center Utrecht (NL)
- Corresponding author
- Berns, Els M. J. J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-17
- Volume
- 9
- Issue
- 9
- Pages
- e103988
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4167545
- OpenAlex
- W2015030879
- Cited by
- 403
- References
- 89
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 30 · 2023: 48 · 2022: 38 · 2021: 54 · 2020: 52 · 2019: 41 · 2018: 27 · 2017: 28 · 2016: 25 · 2015: 21
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-03-23)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Cancer Research UK (15601)
- Universitair Medisch Centrum Utrecht
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- epithelial ovarian cancer, ovarian cancer cell lines, morphological subtypes, high-grade serous carcinoma, low-grade serous carcinoma, tumor heterogeneity, metastasis, prognosis, drug response, preclinical models
- MeSH terms
- Carcinoma, Ovarian Epithelial, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
